Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

With strategics, one crossover on board, HotSpot is likely to raise mezzanine round before exploring IPO

Paul Bonanos, Associate Editor
May 21, 2020 11:05 AM UTC

Allostery company HotSpot has added strategic and crossover investors to the mix for a $65 million series B round designed to take two small molecules into the clinic, but the company believes it will still take a mezzanine round to clear the path for an IPO.

On Thursday, HotSpot Therapeutics Inc. said SR One led the series B funding, which included new investors Tekla Capital Management, MRL Ventures Fund, Solasta Ventures and Brace Pharma via its Cleva Pharma affiliate, as well as founding investors Atlas Venture and Sofinnova Partners...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Hotspot Therapeutics Inc.